Table 1 Assumptions and main parameters used in the base-case analysis
Parameter | Assumptions and values used in the base case |
|---|---|
Country | Peru |
Population | Newborn cohort of 2007 (500,700) [12] |
Perspective | Payers of the healthcare system |
Time horizon | Lifetime |
Comparators | No vaccination, PCV-7, PCV-13, and PHiD-CV |
Indirect effects | None considered in the base-case analysis |
NTHi ID efficacy | 35.3% for PHiD-CV [13] |
Outcomes | ID: meningitis and bacteremia (including long-term sequelae for meningitis) Ambulatory and hospitalized Pneumonia AOM (including long-term sequelae and myringotomy) |
Cross protection | Considered for 6A and 19A in ID |
Vaccine coverage | 95% of the cohort receives full schedule for PHiD-CV and PCV-13; PCV-7 was studied with 83% coverage [5] |
Vaccination schedule | 2 + 1, same for the 3 vaccines: two doses at 2 and 4 months of age and a booster dose at 12 months of age |
Vaccine price | Vaccine prices per dose for PCV-13 (US$ 16.34) and PHiD-CV (US$ 14.24) were obtained from the PAHO Revolving Fund 2012, and PCV-7 (US$ 20.00) from the PAHO Revolving Fund 2010 (last year of availability) |
Duration of immunity | 9Â years, with vaccine efficacy modeled as previously shown for all the outcomes evaluated [11] |
Discounting | 3.5% for costs and health events |